|
FY2025
12 months to Dec 31, 2025
|
FY2024
12 months to Dec 31, 2024
|
|
|---|---|---|
| Cash flows from operating activities | ||
| Consolidated net loss | ||
| Adjustments to reconcile net loss to cash used in operating activities | ||
| Provision for (reversal from) credit losses | ||
| Provision/(reversal) for allowance for credit losses | ||
| Provision for inventory | ||
| Depreciation and amortization expense | ||
| Impairment of Property, plant and equipment | ||
| Amortization of operating and finance right-of-use assets | ||
| (Gain) loss on disposals of property, plant and equipment | ||
| (Reversal from) provision from warranty liability | ||
| (Reversal) provision for warranty liability | ||
| Unrealized gain on short-term investment | ||
| Transaction costs related to the issuance of consultant shares | ||
| Share-based compensation to consultant | ||
| Changes in operating assets and liabilities: | ||
| Notes receivable | ||
| Accounts receivable | ||
| Inventories | ||
| Amounts due from related parties | ||
| Prepaid expenses and other current assets | ||
| Retention receivables | ||
| Long term accounts receivable | ||
| Accounts and notes payable | ||
| Amounts due to related parties | ||
| Contract liabilities | ||
| Accrued expenses and other current liabilities | ||
| Product warranty liability | ||
| Lease liability | ||
| Net cash used in operating activities | ||
| Cash flows from investing activities | ||
| Purchase of property, plant and equipment | ||
| Placement of short-term investments | ||
| Issuance of promissory note receivable | ||
| Net cash used in investing activities | ||
| Cash flows from financing activities | ||
| Capital injection from share capital shareholders | ||
| Proceeds from borrowings from third parties | ||
| Repayments of borrowings to third parties | ||
| Repayment of loan payable with pledged assets | ||
| Proceeds from PIPE financing | ||
| Net cash provided by financing activities | ||
| Effect of foreign currency exchange rate changes on cash, cash equivalents and restricted cash | ||
| Net increase (decrease) in cash, cash equivalents and restricted cash | ||
| Cash and cash equivalents and restricted cash, beginning of year | ||
| Cash and cash equivalents and restricted cash, end of year | ||
| Supplemental disclosures of cash flow information | ||
| Cash paid for interest | ||
| Supplemental disclosures of non-cash flow information | ||
| Right-of-use assets obtained in exchange for lease liabilities | ||
| Unpaid deferred offering cost related with reverse recapitalization | ||
| Net liabilities acquired in the reverse recapitalization | ||
| Issuance of consultant shares | ||
| Settlement from discontinued operations’ receivable | ||
| Cash and cash equivalents, beginning of the year | ||
| Restricted cash, beginning of the year | ||
| Total cash, cash equivalents and restricted cash at beginning of the year | ||
| Cash and cash equivalents, end of the year | ||
| Restricted cash, end of the year | ||
| Total cash, cash equivalents and restricted cash at end of the year |
Loading...
